PL3818048T3 - Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę - Google Patents

Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę

Info

Publication number
PL3818048T3
PL3818048T3 PL19737039.8T PL19737039T PL3818048T3 PL 3818048 T3 PL3818048 T3 PL 3818048T3 PL 19737039 T PL19737039 T PL 19737039T PL 3818048 T3 PL3818048 T3 PL 3818048T3
Authority
PL
Poland
Prior art keywords
morpholine
hydroxyethyl
methyl
crystalline salt
tetrahydrofolic acid
Prior art date
Application number
PL19737039.8T
Other languages
English (en)
Inventor
Rudolf Moser
Viola Groehn
Ruth BOEHNI STAMM
Fritz Blatter
Martin Szelagiewicz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL3818048T3 publication Critical patent/PL3818048T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
PL19737039.8T 2018-07-06 2019-07-02 Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę PL3818048T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18182277 2018-07-06
PCT/EP2019/067692 WO2020007834A1 (en) 2018-07-06 2019-07-02 Crystalline salt comprising 5-methyl-(6s)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine

Publications (1)

Publication Number Publication Date
PL3818048T3 true PL3818048T3 (pl) 2024-03-18

Family

ID=62874791

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19737039.8T PL3818048T3 (pl) 2018-07-06 2019-07-02 Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę

Country Status (11)

Country Link
US (1) US11633400B2 (pl)
EP (1) EP3818048B1 (pl)
JP (1) JP7532336B2 (pl)
CN (1) CN112368269B (pl)
DK (1) DK3818048T3 (pl)
ES (1) ES2966936T3 (pl)
FI (1) FI3818048T3 (pl)
HU (1) HUE064729T2 (pl)
PL (1) PL3818048T3 (pl)
PT (1) PT3818048T (pl)
WO (1) WO2020007834A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
JP5856372B2 (ja) 2008-02-20 2016-02-09 グノーシス・エツセ・ピー・アー 葉酸塩、これらの組成物および使用
WO2013025203A1 (en) * 2011-08-16 2013-02-21 Watson Laboratories, Inc. Resolution of tetrahydrofolic acid derivatives
CN104557937B (zh) * 2012-01-20 2017-03-08 连云港金康和信药业有限公司 (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法
CN102659609A (zh) 2012-05-17 2012-09-12 安润医药科技(苏州)有限公司 非诺贝特酸盐及其制备方法和应用,以及其药物组合物
US20160207925A1 (en) 2013-12-31 2016-07-21 Gianni Fracchia L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof
LT3319959T (lt) * 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
CN106986873B (zh) 2016-01-21 2021-03-30 上海方楠生物科技有限公司 一种5-甲基四氢叶酸的纯化方法
WO2018178142A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline binary sodium salts of 5-methyl-(6s)-tetrahydrofolic acid with organic bases

Also Published As

Publication number Publication date
JP2021529206A (ja) 2021-10-28
DK3818048T3 (da) 2023-11-27
CN112368269A (zh) 2021-02-12
CN112368269B (zh) 2025-04-11
WO2020007834A1 (en) 2020-01-09
ES2966936T3 (es) 2024-04-25
PT3818048T (pt) 2023-12-28
US20210220366A1 (en) 2021-07-22
JP7532336B2 (ja) 2024-08-13
US11633400B2 (en) 2023-04-25
EP3818048A1 (en) 2021-05-12
HUE064729T2 (hu) 2024-04-28
FI3818048T3 (fi) 2023-12-18
EP3818048B1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
IL276509A (en) Heterocyclic compounds as kinase inhibitors
ZA201804870B (en) Acid addition salts of piperazine derivatives
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
WO2016023954A3 (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents
SG11202103823PA (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
IL280841A (en) Succinate and fumarate acid addition salts of piperazine derivatives used as glycosidase inhibitors
SI3412672T1 (sl) Kristalna oblika A 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5H-pirolo(3,2-d)pirimidin -4-amina kot TLR7 agonist, postopek priprave in njena uporaba
EP3592359A4 (en) CRYSTALLINE FORMS OF OBETICHOLIC ACID
PT3817813T (pt) Sais cristalinos de ácido 5metil-(6s)-tetra.hidrofólico e de éster etílico de l-leucina
PL3818048T3 (pl) Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę
PT3398946T (pt) Sal de derivado de morfolina e a sua forma cristalina, bem como método de preparação, composição farmacêutica e a sua utilização
HUE064746T2 (hu) 5-Metil-(6S)-tetrahidrofolsav és l-valin-etilészter kristályos sói
PL3445751T3 (pl) Nowa polimorficzna postać krystalicznej rozuwastatyny wapniowej i nowe procesy otrzymywania krystalicznej i amorficznej rozuwastatyny wapniowej
PT3609894T (pt) Sal de sódio cristalino do ácido 5-metil-(6s)-tetrahidrofólico
HUE064730T2 (hu) 5-Metil-(6S)-tetrahidrofolsavat és L-izoleucin-etilésztert tartalmazó kristályos só
EP3887367A4 (en) CRYSTALLINE SALTS OF CORYDALMINE
SG11202010161UA (en) Meglumine salts of thienopyrimidines
PH12018501314A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
EP3421474A4 (en) NEW CRYSTALLINE FORMS OF (6- (1H-INDAZOLE-6-YL) -N- [4- (4-MORPHOLINYL) PHENYL] IMIDAZO [1,2-A] PYRAZIN-8-AMINE) -METHANESULFONATE
ZA202008062B (en) Pharmaceutically acceptable salts of sepiapterin
HK40042815A (en) Heterocyclic compounds as kinase inhibitors